QQ客服 官方微博 反馈留言

	Hepatitis E vaccine development A 14-year odyssey
	Wu, Ting ; Li, Shao-Wei ; Zhang, Jun ; Ng, Mun-Hon ; Xia, Ning-Shao ; Xia NS(夏宁邵) ; Zhao, Qinjian
	2012-06
关键词	E VIRUS NEUTRALIZATION PROTEIN DISEASE
英文摘要	The first prophylactic vaccine, Hecolin (R), against hepatitis E virus (HEV) infection and the HEV associated disease was approved by China State Food and Drug Administration (SFDA) in December 2011. Key milestones during the 14-year HEV vaccine development are summarized in this short report. After years' innovative research, the recombinant virus-like particle (VLP) based antigen with virion-like epitopes was successfully produced in E. coli production platform at commercial scale. Safety and efficacy of this vaccine was demonstrated in a large scale Phase III clinical trial.
语种	英语
出版者	LANDES BIOSCIENCE
内容类型	期刊论文
源URL	[http://dx.doi.org/10.4161/hv.20042]
专题	公共卫生－已发表论文
推荐引用方式 GB/T 7714	Wu, Ting,Li, Shao-Wei,Zhang, Jun,et al. Hepatitis E vaccine development A 14-year odyssey[J],2012.
APA	Wu, Ting.,Li, Shao-Wei.,Zhang, Jun.,Ng, Mun-Hon.,Xia, Ning-Shao.,...&Zhao, Qinjian.(2012).Hepatitis E vaccine development A 14-year odyssey..
MLA	Wu, Ting,et al."Hepatitis E vaccine development A 14-year odyssey".(2012).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。